Cryopreserved CAR-like NK Cells Pre-Complexed with the CD30/CD16A Bispecific Innate Cell Engager (ICE®) AFM13 for the Treatment of CD30 + Malignancies

被引：1
|
作者：
Reusch, Uwe [1 ]
Ellwanger, Kristina [1 ]
Fucek, Ivica [1 ]
Mueller, Thomas [1 ]
Schniegler-Mattox, Ute [1 ]
Pahl, Jens [1 ]
Tesar, Michael [1 ]
Koch, Joachim [1 ]
机构：
[1] Affimed GmbH, Heidelberg, Germany
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-150552
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3992
引用
收藏
页数：3
相关论文
共 27 条
  • [1] THE BISPECIFIC INNATE CELL ENGAGERS AFM13 (CD30/ CD16A) AND AFM24 (EGFR/CD16A) INCREASE THE FRACTION OF TUMOR TARGET-RESPONSIVE NK CELLS AND BOOST SERIAL KILLING
    Zambarda, Chiara
    Guldevall, Karolin
    Zambarda, Chiara
    Guldevall, Karolin
    Breunig, Christian
    Toullec, Damien
    Fontana, Jacopo
    Pinto, Sheena
    Pahl, Jens
    Wingert, Susanne
    Koch, Joachim
    Oenfelt, Bjorn
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A938 - A938
  • [2] Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood-Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies
    Kerbauy, Lucila N.
    Marin, Nancy D.
    Kaplan, Mecit
    Banerjee, Pinaki P.
    Berrien-Elliott, Melissa M.
    Becker-Hapak, Michelle
    Basar, Rafet
    Foster, Mark
    Melo, Luciana Garcia
    Neal, Carly C.
    McClain, Ethan
    Daher, May
    Cortes, Ana Karen Nunez
    Desai, Sweta
    Lim, Francesca Wei Inng
    Mendt, Mayela Carolina
    Schappe, Timothy
    Li, Li
    Shaim, Hila
    Shanley, Mayra
    Ensley, Emily L.
    Uprety, Nadima
    Wong, Pamela
    Liu, Enli
    Ang, Sonny O.
    Cai, Rong
    Nandivada, Vandana
    Mohanty, Vakul
    Miao, Qi
    Shen, Yifei
    Baran, Natalia
    Fowlkes, Natalie W.
    Chen, Ken
    Muniz-Feliciano, Luis
    Champlin, Richard E.
    Nieto, Yago L.
    Koch, Joachim
    Treder, Martin
    Fischer, Wolfgang
    Okamoto, Oswaldo Keith
    Shpall, Elizabeth J.
    Fehniger, Todd A.
    Rezvani, Katayoun
    CLINICAL CANCER RESEARCH, 2021, 27 (13) : 3744 - 3756
  • [3] The CD30/CD16A RECRUIT T andAb AFM13 activates patient NK cells resulting in specific tumor cell killing
    Rothe, Achim
    Topp, Max S.
    Younes, Anas
    Reusch, Uwe
    Knackmuss, Stefan
    Rajkovic, Erich
    Eichenauer, Dennis A.
    Hummel, Horst
    Reiners, Katrin S.
    Dietlein, Markus
    Kessler, Joerg
    Ravic, Miroslav
    Hucke, Christian
    Zhukovsky, Eugene
    von Strandmann, Elke Pogge
    Engert, Andreas
    CANCER RESEARCH, 2013, 73 (08)
  • [4] Anti-PD-1 to enhance NK-cell cytotoxicity towards CD30+Hodgkin lymphoma induced by CD30/CD16A TandAb AFM13
    Treder, Martin
    Zhao, Xing
    Rajasekaran, Narendiran
    Reusch, Uwe
    Marschner, Jens-Peter
    Kohrt, Holbrook Edwin
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [5] A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells
    Reusch, Uwe
    Burkhardt, Carmen
    Fucek, Ivica
    Le Gall, Fabrice
    Le Gall, Mikaelle
    Hoffmann, Karin
    Knackmuss, Stefan H. J.
    Kiprijanov, Sergej
    Little, Melvyn
    Zhukovsky, Eugene A.
    MABS, 2014, 6 (03) : 727 - 738
  • [6] AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy
    Jingjing Wu
    Jiaping Fu
    Mingzhi Zhang
    Delong Liu
    Journal of Hematology & Oncology, 8
  • [7] AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy
    Wu, Jingjing
    Fu, Jiaping
    Zhang, Mingzhi
    Liu, Delong
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2015, 8
  • [8] Immune checkpoint inhibition by anti-PD-1 or CD137 co-stimulation enhances cytotoxicity towards CD30+ tumors mediated by the bispecific tetravalent CD30/CD16A TandAb AFM13
    Zhao, Xing
    Rajasekaran, Narendiran
    Reusch, Uwe
    Marschner, Jens-Peter
    Treder, Martin
    Kohrt, Holbrook E.
    CANCER RESEARCH, 2016, 76
  • [9] Clinical and Biological Evaluation of the Novel CD30/CD16A Tetravalent Bispecific Antibody (AFM13) in Relapsed or Refractory CD30-Positive Lymphoma with Cutaneous Presentation: A Biomarker Phase Ib/IIa Study (NCT03192202)
    Sawas, Ahmed
    Elgedawe, Hager
    Vlad, George
    Lipschitz, Mikel
    Chen, Pei-Hsuan
    Rodig, Scott J.
    Lue, Jennifer Kimberly
    Deng, Changchun
    Amengual, Jennifer E.
    Hay, Maher Abdul
    Khan, Karen
    Atkins, Laine E.
    Rada, Aishling M.
    Geskin, Larisa
    O'Connor, Owen A.
    BLOOD, 2018, 132
  • [10] Title: Clinical and Biological Evaluation of the Novel CD30/CD16A Tetravalent Bispecific Antibody (AFM13) in Relapsed or Refractory CD30-Positive Lymphoma with Cutaneous Presentation: A Biomarker Phase Ib/IIa Study (NCT03192202)
    Sawas, Ahmed
    Chen, Pei-Hsuan
    Lipschitz, Mikel
    Rodig, Scott
    Vlad, George
    BLOOD, 2020, 136
123